Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Other

Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine(TM) as a Promising New Anti-Inflammatory Agent

By The Northwire Desk — AI Analysis Dec 04, 2025 · 08:45 GSD · 0.22 Devonian Health Group Inc.
GSD · Price

Executive Summary

  • Devonian Health Group announced the publication of a peer‑reviewed study in Biomedicines demonstrating that its lead candidate Thykamine™ shows superior anti‑inflammatory potency versus six widely used drugs, with a favorable safety profile.
  • The data support Thykamine™ as a strong next‑generation therapeutic for chronic inflammatory and autoimmune conditions, potentially expanding the company’s pipeline value.
  • The release includes quotes from Chairman & CEO Dr. André P. Boulet emphasizing the paradigm‑shift potential of Thykamine™ in treating inflammation‑driven diseases.

Key Details

  • Study Publication: “Thykine™: A New Player in the Field of Anti‑Inflammatory Drugs,” Biomedicines (Vol 13, Issue 12, Article 2938).
  • Authors & Institutions: Dr. Charles Lynde (U‑Toronto), Prof. Louis Flamand (Université Laval), Vincent McCarty & Dr. John Sampalis (McGill University).
  • Comparators Tested: Six anti‑inflammatory agents – corticosteroids (betamethasone, clobetasol, hydrocortisone, prednisone) and non‑steroidal drugs (crisaborole, pimecrolimus).
  • In‑vitro Model Findings:
  • Thykamine™ inhibited MCP‑1, MIP‑1α, and MIP‑1β secretion with significantly greater potency than all comparators.
  • RANTES suppression was comparable to or better than most tested agents.
  • Effects observed at lower concentrations; no detectable cytotoxicity.
  • Therapeutic Implications: Multi‑target anti‑inflammatory activity combined with a benign safety profile positions Thykamine™ for chronic conditions such as ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and broader autoimmune disorders.
  • Platform & Patent Coverage: Thykamine™ originates from Devonian’s SUPREX™ platform; patents issued in North America, Europe, and Asia.
  • CEO Quote: “The results with Thykamine™ are very encouraging… offering a real possibility of bridging the gap between effectiveness and tolerability.” – Dr. André P. Boulet, Chairman & CEO.

Notable Quotes

“Thykamine™ offers a real possibility of bridging that gap — combining potent suppression of harmful inflammation with a gentler safety profile. We believe this could represent a paradigm shift in how we manage chronic inflammatory and autoimmune conditions.” – Dr. André P. Boulet, Chairman & CEO, Devonian Health Group Inc.

Read the original news release →

More from Devonian Health Group Inc.

Jun 29, 2026 · 20:00

Devonian's cash runway narrows to months as Altius revenue vanishes and pipeline remains pre-revenue

Earnings Mar 25, 2026 · 16:22

Devonian Health Faces Liquidity Cliff as Distribution Revenue Dries Up and Biotech Pivot Demands Fresh Capital

Earnings Feb 19, 2026 · 09:00

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Other Feb 17, 2026 · 09:00

Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

M&A / Property Feb 12, 2026 · 19:58

Devonian preclinical data support Thykamine

Other Feb 12, 2026 · 09:00

Devonian reports additional molecular data from MASH liver study

Other